Shots:
The EC has granted marketing authorization for Zokinvy in children & young adults with HGPS & processing-deficient PL. Zokinvy is expected to be available, after successful completion of the reimbursement discussions country-by-country
The EC authorization was based on 2 pivotal trials which showed a 72% reduction in risk of death & extended life by an av. of 4.3yrs. in children & young adults with HGPS
The marketing authorization will be valid in all 27 EU member states, Iceland, Liechtenstein & Norway. Zokinvy is the first approved treatment in the EU & is currently under the MHRA’s review as part of the EC Decision Reliance Procedure
Ref: PRNewswire | Image: Eiger
